High-dose cytarabine (HD Ara-C) has been shown to be effective for both the induction and consolidation of complete remission (CR) in patients with acute myeloblastic leukaemia (AML) (Mayer et al, 1994; Mitus et al, 1995; Bishop et al, 1996; Weick et al, 1996; Cole & Gibson, 1997; Fopp et al, 1997; Rowe & Tallman, 1997) . In patients below 60 years of age who were treated using chemotherapy alone without transplant, a randomized study of various doses of Ara-C administered for consolidation has shown that, in younger patients, the higher the dose of Ara-C the better the outcome. In the South-West Oncology Group±Eastern Cooperative Oncology Group±Cancer and Leukaemia Study Group B (SWOG±ECOG±CALGB) (Cassileth et al, 1998) intergroup randomized study that compared conventional chemotherapy using HD Ara-C with allogeneic (BMT) and autologous (ABMT) stem cell transplantations, consolidation with HD Ara-C led to a better outcome than the transplantations. This was as a result of salvage by autologous or allogeneic bone marrow transplantation in the patients who relapsed after HD Ara-C. Although bothbenefit or would increase toxicity. To answer the question, we retrospectively analysed results from transplants reported to the registry of the Acute Leukaemia Working Party of the European Co-operative Group for Blood and Marrow Transplantation (EBMT).
PATIENTS AND METHODS
Patients. The study included 1672 patients with AML in first complete remission (CR1). These patients were transplanted between 1980 and 1995 and were reported to the Acute Leukaemia Working Party of the EBMT. Eight hundred and forty-six were transplanted with autologous stem cells and 826 with BMT from an HLA-matched sibling. Patients and transplant characteristics are given in Table I . The dose intensity of Ara-C was defined as follows: standard dose (SD) for patients receiving 100±200 mg/m 2 /d for 5±10 d, high dose (HD) for patients receiving 1´5±3 g/m 2 /d for 4±6 d. Patients receiving doses falling between these two groups were included in an intermediate group (ID) . Following these criteria, 820 patients among the autologous group received Ara-C for induction and 803 patients received Ara-C for postremission therapy. For induction, 767 patients received SD and 31 patients received HD. For post-remission therapy, 358 patients and 284 patients received SD and HD respectively. Among the BMT group, 809 patients received Ara-C for induction and 670 patients received Ara-C for post-remission treatment. During induction, 733 patients were treated with SD and 45 patients with HD. For post-remission therapy, 393 patients received SD and 201 patients received HD.
Statistical methods. Data were analysed from December 1998. All analyses were performed using the SPSS statistical package software. Leukaemia-free survival (LFS), relapse incidence (RI) and transplant-related mortality No, no Ara-C; LD, low-dose Ara-C; SD, standard-dose Ara-C; ID, intermediate dose Ara-C; HD, high-dose Ara-C; SCT, stem cell transplantation; CR1, first complete remission; TBI, total body irradiation; WBC, white blood cells at diagnosis; GVHD, graftversus-host disease; CSA, cyclosporin A; MTX, methotrexate; aGVHD, acute graft-versus-host disease; cGVHD, chronic graftversus-host disease.
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Comparison of these data was based on results from log rank tests. The Cox regression model was applied to assess the prognostic value of both patient and treatment characteristics in relation to relapse, LFS and TRM. Variables tested with the doses of Ara-C were age, gender, white blood cell count (WBC) at diagnosis, French±American±British (FAB) classification, cytogenetics, interval between diagnosis and CR, interval between diagnosis and BMT, conditioning LFS, leukaemia-free survival; RI, relapse incidence; TRM, transplant-related mortality; SE, standard error of the mean; No, no Ara-C; SD, standard dose Ara-C; ID, intermediate dose Ara-C; HD, high-dose Ara-C. * Among the 45 patients having received HD at induction 16 received HD Ara-C twice and the delay between diagnosis and CR1 was prolonged in this restricted population (median, 61 d vs. 42 d for the remaining patients).
LFS, leukaemia-free survival; RI, relapse incidence; TRM, transplant-related mortality; SE, standard error of the mean; No, no Ara-C; SD, standard-dose Ara-C; ID, intermediate-dose Ara-C; HD, high-dose Ara-C. regimen, bone marrow purging, source of stem cells, graftversus-host disease (GVHD) prophylaxis, acute and/or chronic GVHD and the year of transplantation. The characteristics of the three groups of patients who received standard dose (SD), intermediate dose (ID) or HD Ara-C were compared using the x 2 test for qualitative variables and the Kruskall±Wallis test for continuous variables. All variables that were associated with outcome and that showed a P-value less than 0´2 and/or that had a different distribution between groups were included in the Cox model.
RESULTS

Outcome of autografted patients
For ABMT, the dose intensity of Ara-C, whether evaluated at induction or after remission, did not influence LFS, RI or TRM at 5 years (Table II) .
Outcome of allografted patients After BMT, relapse incidence was more important for patients induced with HD Ara-C than for patients induced with SD Ara-C. There was no statistical difference between TRM and LFS. No difference was found among the three groups of Ara-C prescribed as post-remission therapy in terms of probability of LFS, RI or TRM at 5 years (Table III) .
Prognostic factors other than dose of Ara-C: univariate analysis In the ABMT patients, age, date of transplant, FAB M3, purging and interval between diagnosis and remission all had a prognostic value for relapse and LFS.
In the BMT patients, age, interval between diagnosis and CR1, WBC at diagnosis and T-cell depletion influenced LFS. WBC at diagnosis, T-cell depletion and cytogenetics influenced relapse. TRM was influenced by age, year of transplant, total body irradiation (TBI) and interval between diagnosis and CR1.
Acute GVHD was associated with a lower relapse incidence, a higher TRM and a lower LFS. Chronic GVHD was not analysed owing to a lack of data.
Results of cytogenetics were available for 425 patients. Table IVA shows the distribution of patients within the good, standard and poor risk categories according to the modified Chicago classification. The distribution of the cytogenetic categories in relation to the dose of Ara-C did not show any unbalance (Table IVB) . As previously shown by the EBMT (Ferrant et al, 1997) , the outcome after either autografting or allografting was worse in the poor risk category patients (Table IVC) . The distribution of the cytogenetic subgroups was identical between the three doses of Ara-C, but it was not possible to include cytogenetics in the multivariate analysis owing to the small number of patients in each subgroup.
Prognostic factors: multivariate analysis
Variables differing significantly or recognized as potential prognostic factors were included as covariates in the multivariate analysis. The dose of Ara-C given at induction or after remission had no influence on the outcome of ABMT in terms of LFS, RI or TRM. Other independent /l); T depletion; aGVHD (time-dependent covariate). SCT, stem cell transplantation; TBI, total body irradiation; CR1, first complete remission; WBC, white blood cell at diagnosis; aGVHD, acute graft-versus-host disease; LFS, leukaemia-free survival; RI, relapse incidence; TRM, transplant-related mortality; RR, relative risk; CI, confidence interval. factors are shown in Table V. In the BMT patients, no influence of SD or HD Ara-C (Table VI) was observed.
DISCUSSION
Uncertainty remains about optimal remission and postremission Ara-C regimens for de novo AML outside the context of stem cell transplantation (SCT). Although pilot studies suggested a significant improvement with higher doses, there have been only two prospective randomized trials using HD Ara-C as part of the standard induction. In the SWOG study (Weick et al, 1996) , patients were randomized for induction between SD or HD Ara-C and both groups received daunorubicin (DNR). Complete responders to HD Ara-C received an additional course of HD Ara-C and DNR. Complete responders to SD were randomized to receive SD plus DNR or HD plus DNR.There was no advantage for HD Ara-C in terms of CR rates. The LFS was better in patients treated with HD Ara-C, but was associated with significantly more lethal toxicities. Similar findings were reported by the Australian Leukaemia Study Group (Bishop et al, 1996) in a study that compared HD Ara-C plus daunorubicin and etoposide with SD Ara-C plus daunorubicin and etoposide. Patients in CR tended to survive longer with HD Ara-C, but there was no statistical difference between the two arms in terms of overall survival.
More frequently, schedules including HD Ara-C have been included as post-remission intensification therapy. The Cancer and Leukaemia Study Group B (CALGB) (Mayer et al, 1994) At 4 years, the disease-free survival rate (DFS) was significantly in favour of the higher dose in patients less than 60 years of age. The patients also experienced significant dose-related toxicities. The Swiss Group for Clinical Cancer Research (Fopp et al, 1997) has recently published results suggesting that Ara-C dose intensity might be more important than the total cumulative dosage. The question of the type of chemotherapy given before SCT has never been analysed in terms of dose intensity. Several studies have investigated the optimal interval between CR1 and SCT. This approach has always been limited by biases such as relapse with time, complications that delay transplant or poor haematological recovery for autologous stem cell harvest (Gorin, 1998) . The best chemotherapy regimen available is not necessarily the best option before transplantation. More frequently now, BMT is performed quickly after achieving CR1, whereas the therapies between CR1 and ABMT are quite heterogeneous in length and intensity. In some studies, ABMT can be considered as an additional treatment, whereas in others it takes the place of another intensification.These could be the major explanations for the differences observed between randomized trials (Zittoun et al, 1995; Reiffers et al, 1996; Harousseau et al, 1997; Burnett et al, 1998; Cassileth et al, 1998) showing various differences between chemotherapy and ABMT according to different designs and timing of transplantation.
Apart from the dose of Ara-C, the type and dose of anthracycline used, both in induction and after remission, may be important, especially when considering idarubicin. From the data reported here, we can speculate that highdose therapy administered with SCT could abrogate the advantage of previous intermediate or HD Ara-C.
HD Ara-C improves LFS in chemotherapy-treated AML patients despite higher toxicity, including Ara-C-related mortality. Patients who died as a result of Ara-C toxicity could not proceed to BMT and therefore the present study has focused on a selected group of patients that should have favoured the appearance of a possible beneficial effect of Ara-C after BMT. However, no such effect was found.
Because in vivo purging with HD Ara-C has been used in several trials (Zittoun et al, 1995; Harousseau et al, 1997; Schiller et al, 1997; Burnett et al, 1998; Pavlovsky et al, 1998) and has a major disadvantage in prolonging the delay to platelet recovery, its use before ABMT should be avoided. Presently, the choice between conventional chemotherapy and BMT is being approached in a different way, according to the prognostic factors at diagnosis, such as cytogenetics (Ferrant et al, 1997; Bloomfield et al, 1998; Grimwade et al, 1998) . Some current trials are now stratifying treatment approach by using cytogenetics and by considering HD Ara-C as the option of choice for core binding factor-type cytogenetic abnormalities in adult AML with BMT being reserved for relapse. However, we did not analyse patients with inv(16) and t(8;21) at diagnosis separately because of their low number and also to avoid the statistical problems associated with subgroup analysis.
In conclusion, to analyse the impact of HD Ara-C given at induction or post-remission therapy before subsequent intensification with SCT, we have retrospectively studied data reported to the EBMT. Three subgroups have been compared. This study clearly shows that increasing the dose of Ara-C before SCT does not give any advantage in terms of outcome. HD Ara-C does not seem to be the gold standard before BMT or ABMT and probably should be dedicated to certain subtypes of AML that can be treated using chemotherapy alone.
